Forget Fibrils: Lewy Pathology Is More Lipid Than Protein
An electron microscopy study reveals a jumbled mess of membrane chunks and malfunctioning organelles, bound together by phosphorylated or truncated α-synuclein.
1380 RESULTS
Sort By:
An electron microscopy study reveals a jumbled mess of membrane chunks and malfunctioning organelles, bound together by phosphorylated or truncated α-synuclein.
Taking a stab at secondary prevention, the four-year Phase 3 trial will assess the antibody’s ability to slow slippage in 1,200 cognitively healthy, amyloid-positive people.
The autopsy of a woman with a the PSEN1 Paisa mutation plus a homozygous ApoE3 variant showed an unusual distribution of tau tangles. Gene-expression studies pinpointed vulnerable neurons that were spared, and riled-up microglia in tangle-ridden zones.
α-Synuclein seed amplification assays identify people with LBD. They may outperform clinical diagnosis, and hint that dementia with Lewy bodies might be overdiagnosed.
In contrast to phospho-tau species that mirror amyloid, CSF MTBR-tau-243 reflects tau-PET. It fell upon treatment with an antibody against tau’s midsection.
In a Phase 1 trial of Roche’s RG6289, both plasma and CSF Aβ37 climbed, while Aβ42 fell.
Twelve people heterozygous for this protective variant were still sharp seven years after their expected age of AD onset. One had fewer tangles than expected.
Envelope proteins from endogenous retroviruses help shuttle tau seeds between cells. Could HERVs fuel tauopathies?
Alzheimer’s researchers got their first look at data from the positive Phase 3 trial. Many expect this antibody to become the third approved immunotherapy for AD.
When it comes to human tests of prospective Alzheimer disease treatments, researchers have learned to be humble...
The International Conference AD/PD has been growing steadily; this year...
Many studies using Pittsburgh Compound-B (PIB) have found a fair percentage of normal elderly walking around with heads full of amyloid...
The inside of a cell is a very busy place...
Three groups presented results of their ongoing effort to incorporate scientific advances of the past quarter-century into a revision of the current diagnostic AD criteria...
This story presents an update from this year's ICAD conference, together with an extended Q&A with the developer of RemberTM, Claude Wischik...